World's Best Scientists 2026 revealed!
Jean-Pierre Bronowicki

Jean-Pierre Bronowicki

Jean-Pierre Bronowicki publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Jean-Pierre Bronowicki sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

The last bar groups every scientist with 1,796 publications or more.

Jean-Pierre Bronowicki D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Jean-Pierre Bronowicki sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

The last bar groups every scientist with 217 D-Index or more.

Overview

Jean-Pierre Bronowicki is affiliated with the University Hospital of Nancy in France. Their research primarily focuses on hepatology, epidemiology, pathology and forensic medicine, surgery, and pulmonary and respiratory medicine within the broader field of medicine. The scientist has produced a significant number of publications related to liver diseases and cancer mechanisms, contributing extensively to the understanding and treatment of hepatocellular carcinoma and liver disease diagnosis and treatment.

Their main topics of work include:

  • Hepatocellular Carcinoma Treatment and Prognosis
  • Liver Disease Diagnosis and Treatment
  • Hepatitis C virus research
  • Liver Disease and Transplantation
  • Hepatitis B Virus Studies
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Cancer Mechanisms and Therapy

Jean-Pierre Bronowicki has collaborated frequently with several co-authors over the course of their career. These include Nathalie Ganne-Carrié, Marc Bourlière, Victor de Lédinghen, Stanislas Pol, and Pierre Nahon, with each contributing to multiple joint publications.

Their published work appears predominantly in a range of scientific journals with a strong emphasis on hepatology and oncology fields. Frequent publication venues include:

  • Journal of Hepatology
  • JHEP Reports
  • Clinics and Research in Hepatology and Gastroenterology
  • Journal of Clinical Oncology
  • The Lancet

Some recent papers authored or co-authored by Jean-Pierre Bronowicki are:

  • Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial (2023, The Lancet)
  • Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial (2023, The Lancet Oncology)
  • Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (2024, Annals of Oncology)
  • Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study (2025, The Lancet)
  • Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status (2020, Journal of Hepatology)

Best Publications

  • Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

    Jordi Bruix;Shukui Qin;Philippe Merle;Alessandro Granito

  • Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.

    Christophe Hézode;Nicole Forestier;Geoffrey Dusheiko;Peter Ferenci

  • Regression of Splenic Lymphoma with Villous Lymphocytes after Treatment of Hepatitis C Virus Infection

    Olivier Hermine;François Lefrère;Jean-Pierre Bronowicki;Xavier Mariette

  • Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial

    Valérie Vilgrain;Valérie Vilgrain;Helena Pereira;Eric Assenat;Boris Guiu

  • Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study

    Fabrice Carrat;Hélène Fontaine;Céline Dorival;Mélanie Simony

  • Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study.

    Richard Moreau;Francois Durand;Thierry Poynard;Christian Duhamel

  • Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study.

    Caroline Charlier;Élodie Perrodeau;Alexandre Leclercq;Alexandre Leclercq;Benoît Cazenave

  • A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis.

    Christophe Corpechot;Olivier Chazouillères;Alexandra Rousseau;Antonia Le Gruyer

  • Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications

    Pierre Nahon;Pierre Nahon;Valérie Bourcier;Richard Layese;Etienne Audureau

  • Patient-to-Patient Transmission of Hepatitis C Virus during Colonoscopy

    Jean-Pierre Bronowicki;Véronique Venard;Christine Botté;Nathalie Monhoven

  • Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890

    Christophe Hézode;Hélène Fontaine;Céline Dorival;Dominique Larrey

  • All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study

    Michael Peter Manns;Stanislas B Pol;Ira M Jacobson;Patrick M Marcellin

  • Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities.

    Jean‐Claude Trinchet;Cendrine Chaffaut;Valérie Bourcier;Françoise Degos

  • Sulfate‐reducing bacteria in human feces and their association with inflammatory bowel diseases

    Julien Loubinoux;Julien Loubinoux;Jean-Pierre Bronowicki;Ines A.C. Pereira;Jean-Louis Mougenel

  • Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study

    Jorge A. Marrero;Masatoshi Kudo;Alan P. Venook;Sheng Long Ye

  • Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial

    Xavier Forns;Eric Lawitz;Stefan Zeuzem;Ed Gane

  • Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)

    Marc Bourlière;Jean Pierre Bronowicki;Victor de Ledinghen;Christophe Hézode

  • Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and Cirrhosis

    Christophe Hézode;Helene Fontaine;Celine Dorival;Fabien Zoulim

  • Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+)

    Vincent Leroy;Peter W Angus;Jean-Pierre Bronowicki;Gregory J Dore

  • Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: The ANRS HCEP-23 study

    Jean-Pierre Zarski;Nathalie Sturm;Jérôme Guechot;Adeline Paris

Frequent Co-Authors

Marc Bourlière
Marc Bourlière Hôpital Saint Joseph
Dominique Larrey
Dominique Larrey University of Montpellier
Stanislas Pol
Stanislas Pol Université Paris Cité
Christophe Hézode
Christophe Hézode Université Paris Cité
Albert Tran
Albert Tran Inserm : Institut national de la santé et de la recherche médicale
Victor de Ledinghen
Victor de Ledinghen Grenoble Alpes University
Patrick Marcellin
Patrick Marcellin Université Paris Cité
Philippe Mathurin
Philippe Mathurin University of Lille
Laurent Alric
Laurent Alric Federal University of Toulouse Midi-Pyrénées

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in medicine but seeking alternatives to the traditional path of medical school, there are a variety of flexible and rewarding online degree options. For those looking to enter the field quickly, consider accelerated LPN programs, which enable you to become a Licensed Practical Nurse in less time and start your healthcare career sooner.

For nurses wishing to specialize, there are options such as the shortest online pmhnp programs, ideal for those passionate about mental health and pursuing nurse practitioner roles.

Not all healthcare careers involve direct patient care. Students interested in the business and management side of healthcare should look into a health care administration online degree. For those aiming to advance further, a master's in healthcare administration online can lead to leadership positions across hospitals, clinics, and health organizations.

Each of these pathways offers the flexibility of online study and can open doors to fast-growing roles in the healthcare industry.

Best Scientists Citing Jean-Pierre Bronowicki

Trending Scientists

Recently Published Articles